<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953235</url>
  </required_header>
  <id_info>
    <org_study_id>GO-005</org_study_id>
    <nct_id>NCT03953235</nct_id>
  </id_info>
  <brief_title>A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens</brief_title>
  <official_title>A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gritstone Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gritstone Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical&#xD;
      activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in&#xD;
      combination with immune checkpoint blockade, in patients with advanced or metastatic&#xD;
      non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and&#xD;
      shared neoantigen-positive tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations can present peptides&#xD;
      containing these mutations as non-self antigens in the context of HLA on the tumor cell&#xD;
      surface. A fraction of mutated peptides result in neoantigens capable of generating T-cell&#xD;
      responses that exclusively target tumor cells. Some of these tumor-specific neoantigens are&#xD;
      known or expected to be common across a subset of patients and are called shared neoantigens.&#xD;
      This study aims to target shared neoantigens using a heterologous prime/boost therapeutic&#xD;
      vaccine approach (GRT-C903 first followed by GRT-R904) in combination with checkpoint&#xD;
      blockade to stimulate an immune response. This study will explore the safety and early&#xD;
      clinical activity of this neoantigen-based immunotherapy intended to induce T-cell responses&#xD;
      specific for the shared neoantigens contained within the therapeutic vaccine. Phase 1 will&#xD;
      test multiple doses and combinations with checkpoint blockade and Phase 2 will test for early&#xD;
      signs of clinical activity using a vaccine regimen based on Phase 1 data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs)</measure>
    <time_frame>Initiation of study treatment through 100 days post-last dose (up to approximately 27 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) in Phase 2 using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 27 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904</measure>
    <time_frame>Up to approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the immune response to the neoantigens encoded by GRT-C903 and GRT-R904</measure>
    <time_frame>Baseline to end of treatment (up to approximately 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Phase 1 using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) using RECIST v1.1</measure>
    <time_frame>Initiation of study treatment until disease progression (up to approximately 27 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Shared Neoantigen-Positive Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRT-C903&#xD;
GRT-R904&#xD;
nivolumab&#xD;
ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GRT-C903&#xD;
GRT-R904&#xD;
nivolumab&#xD;
ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GRT-C903</intervention_name>
    <description>a shared neoantigen cancer vaccine prime</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GRT-R904</intervention_name>
    <description>a shared neoantigen cancer vaccine boost</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>anti-CTLA-4 monoclonal antibody</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide a signed and dated informed consent form prior to initiation of study-specific&#xD;
             procedures.&#xD;
&#xD;
          -  Patients with the indicated advanced or metastatic solid tumor as follows:&#xD;
&#xD;
               1. Microsatellite-stable colorectal cancer (MSS-CRC) who are currently receiving&#xD;
                  systemic treatment with a fluoropyrimidine and oxaliplatin and/or irinotecan that&#xD;
                  may include a VEGF or EGFR targeting therapy as their 1L therapy for metastatic&#xD;
                  disease OR who have experienced disease progression following treatment with a&#xD;
                  fluoropyrimidine, oxaliplatin, and irinotecan that may include a VEGF or EGFR&#xD;
                  targeting therapy and have not received additional lines of systemic therapy in&#xD;
                  the metastatic setting.&#xD;
&#xD;
               2. Non-small cell lung cancer (NSCLC) who are currently receiving systemic treatment&#xD;
                  with an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based&#xD;
                  chemotherapy OR who have experienced disease progression following treatment with&#xD;
                  an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based&#xD;
                  chemotherapy (or anti-PD-(L)1 alone if patient refuses platinum-based&#xD;
                  chemotherapy), and have not received additional lines of systemic therapy in the&#xD;
                  metastatic setting.&#xD;
&#xD;
               3. Pancreatic ductal adenocarcinoma (PDA) who are currently receiving systemic&#xD;
                  cytotoxic chemotherapy as their 1L therapy for metastatic disease OR who have&#xD;
                  experienced disease progression on 1L systemic cytotoxic chemotherapy and have&#xD;
                  received no more than 1 prior line of therapy in the metastatic setting.&#xD;
&#xD;
               4. Any solid tumor histology where the patient has experienced disease progression&#xD;
                  with all available therapies known to confer clinical benefit&#xD;
&#xD;
          -  Patient's tumor possesses one of the mutations listed below, and is determined to&#xD;
             express a HLA allele for antigen presentation of the identified tumor mutation:&#xD;
&#xD;
        BRAF_G466V // CTNNB1_S37F // CTNNB1_S45F // CTNNB1_S45P // CTNNB1_T41A //&#xD;
        ERBB2_Y772_A775dup // KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V //&#xD;
        KRAS_G13D // KRAS_Q61H or NRAS_Q61H // KRAS_Q61K or NRAS_Q61K // KRAS_Q61L or NRAS_Q61L //&#xD;
        KRAS_Q61R or NRAS_Q61R // TP53_K132E // TP53_K132N // TP53_R213L // TP53_R249M //&#xD;
        TP53_S127Y&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1&#xD;
&#xD;
          -  Adequate organ function, as measured by laboratory values (criteria listed in&#xD;
             protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors with genetic characteristics as follows:&#xD;
&#xD;
               1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,&#xD;
                  RET, or TRK&#xD;
&#xD;
               2. Patients with known MSI-high disease based on institutional standard&#xD;
&#xD;
          -  Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a&#xD;
             vaccination&#xD;
&#xD;
          -  Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant&#xD;
             bruising or bleeding following IM injections or blood draws&#xD;
&#xD;
          -  History of allogenic/solid organ transplant&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Active tuberculosis or recent (&lt;2 week) clinically significant infection, or evidence&#xD;
             of active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Known history of positive test for human immunodeficiency (HIV) or known acquired&#xD;
             immunodeficiency syndrome (AIDS)&#xD;
&#xD;
        Complete inclusion and exclusion criteria are listed in the clinical study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andy Ferguson</last_name>
    <phone>857-327-9816</phone>
    <email>aferguson@gritstone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>New Patient Services</last_name>
      <phone>800-826-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>310-206-2632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine, Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Martinez-Caro Aguado</last_name>
    </contact>
    <contact_backup>
      <email>Phase1trials@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaina Lileton</last_name>
      <email>liletona@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmos</last_name>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirin Pillai</last_name>
    </contact>
    <contact_backup>
      <email>pillais@mskcc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Haskins</last_name>
      <email>robert.haskins@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dee McComb</last_name>
      <email>davinia.mccomb@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seema Prasad</last_name>
    </contact>
    <contact_backup>
      <email>SPrasad1@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoantigen cancer vaccine</keyword>
  <keyword>shared neoantigen</keyword>
  <keyword>GRT-C903</keyword>
  <keyword>GRT-R904</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

